173 related articles for article (PubMed ID: 21182993)
1. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.
Krupa M; Canamero M; Gomez CE; Najera JL; Gil J; Esteban M
Vaccine; 2011 Feb; 29(7):1504-13. PubMed ID: 21182993
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen.
Cole G; Ali AA; McErlean E; Mulholland EJ; Short A; McCrudden CM; McCaffrey J; Robson T; Kett VL; Coulter JA; Dunne NJ; Donnelly RF; McCarthy HO
Acta Biomater; 2019 Sep; 96():480-490. PubMed ID: 31299353
[TBL] [Abstract][Full Text] [Related]
3. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.
Xiao L; Joo KI; Lim M; Wang P
PLoS One; 2012; 7(11):e48866. PubMed ID: 23139820
[TBL] [Abstract][Full Text] [Related]
6. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
7. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
Simons BW; Cannella F; Rowley DT; Viscidi RP
Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
9. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice.
Yang D; Holt GE; Velders MP; Kwon ED; Kast WM
Cancer Res; 2001 Aug; 61(15):5857-60. PubMed ID: 11479226
[TBL] [Abstract][Full Text] [Related]
10. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
[TBL] [Abstract][Full Text] [Related]
11. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
12. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
Knudsen ML; Ljungberg K; Tatoud R; Weber J; Esteban M; Liljeström P
PLoS One; 2015; 10(2):e0117042. PubMed ID: 25643354
[TBL] [Abstract][Full Text] [Related]
13. Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse.
Guo Q; Wang L; Xu P; Geng F; Guo J; Dong L; Bao X; Zhou Y; Feng M; Wu J; Wu H; Yu B; Zhang H; Yu X; Kong W
Oncoimmunology; 2020 Nov; 9(1):1841392. PubMed ID: 33224629
[TBL] [Abstract][Full Text] [Related]
14. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
15. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
16. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
17. [Prokaryotic expression, purification and antigenicity identification of mouse prostate stem cell antigen].
Dong J; Luo J; Yan J; Zhang L; Gao J; Yu J
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Apr; 32(4):502-6. PubMed ID: 22543130
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D.
Meseda CA; Stout RR; Weir JP
Viral Immunol; 2006; 19(2):250-9. PubMed ID: 16817767
[TBL] [Abstract][Full Text] [Related]
19. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
Hodge JW; Higgins J; Schlom J
Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
